Chemical formula: C₁₉H₁₉ClN₆O₂ Molecular mass: 398.85 g/mol PubChem compound: 67171867
Darolutamide is indicated for:
Population group: men, only adults (18 years old or older)
Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: men, only adults (18 years old or older)
Darolutamide is indicated for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Darolutamide is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
